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The term Hereditary Nonpolyposis Colorectal Cancer,
or HNPCC, has been less used for naming the classical
autosomal dominantly inherited susceptibility to cancer
[1]. As this susceptibility applies to tumors from differ-
ent primary sites other than but including colorectal
cancer (CRC), the term Lynch Syndrome (LS) is a less
restrictive name. Lynch Syndrome is characterized by an
autosomal dominantly inherited susceptibility to cancer,
caused by inherited germline mutations in the mismatch
repair (MMR) genes. It is characterized by early age of
onset, predilection to the proximal colon, multiple pri-
mary CRCs, and extracolonic tumors, particularly endo-
metrium carcinoma (EC) [2,3].
To establish a profile of the disease, a better definition of
the spectrum of related tumors has been a constant con-
cern [4,5]. It is therefore expected to find heterogeneity
among the families regarding the susceptibility to develop
tumors in different specific sites. The risk of cancer in fact
varies among families with LS, although the variation does
not necessarily result from genetic heterogeneity. The
standards of environmental exposure must contribute to
the differential gene expression, justifying at least in part
this heterogeneity [6].
LS accounts for 2%–5% of all CRC cases [7]. In fact, it
is believed that 20% to 30% of patients with CRC pre-
sent some type of genetic susceptibility, but without
meeting criteria for known typical syndromes. However,
new cancer cases in the patient’s family or supplemental
information on previously unknown cases can lead to a
reclassification that may characterize a typical syndrome.
In other situations, despite the lack of clinical criteria
for determining an inherited character, molecular
inquiry can define the diagnosis of inherited syndrome.
For these reasons, even in the absence of typical clinical
characterization, criteria must be used to direct the
inquiry of an inherited condition.
The spectrum of extracolonic tumors in LS began to be
the subject of several publications in which the most
common cancers found were those affecting the endome-
trium, the stomach and the urinary tract [8-14]. Watson
and Lynch [6] calculated the frequency of cancer in other
specific sites in 1,300 high-risk individuals from 23
families having LS and demonstrated a significant
increase of the risk of developing cancer in the stomach
(RR:4.1), small bowel (RR:25), kidneys (RR:3.2), ureter
(RR:22), and ovary (RR:3.5). The proposed extracolonic
cancers associated with LS are endometrium, stomach,
ovary, small bowel, ureter, renal pelvis, brain, and hepato-
biliary tract. Among these tumors, endometrium, ureter,
renal pelvis, and small bowel cancers present the highest
relative risk, and are therefore the most specific for LS.
The Amsterdam criteria for clinical diagnosis of LS are:
(1) at least three relatives must have histologically verified
CRC, endometrium, ureter, renal pelvis, or small bowel
cancer; (2) one must be a first-degree relative of the
other two; (3) at least two successive generations must be
affected; (4) at least one of the relatives with cancer must
have received the diagnosis before age 50; and (5) familial
adenomatous polyposis must have been excluded.
Because there are families with an MMR mutation pre-
sent exclusively in patients with endometrial cancer with-
out CRC, the requirement of at least one case of CRC
was suppressed [15,16].
Patients with LS may also have sebaceous adenomas,
sebaceous carcinomas, and multiple keratoacanthomas,
findings consonant with Torre’s syndrome variant
[17,18]. The definition of LS includes a familial cluster-
ing of colorectal and/or endometrial cancer and as asso-
ciated cancers stomach, ovary, ureter/renal pelvis, brain,
small bowel, hepatobiliary tract, and skin (sebaceous
tumors) tumors [15,19].
As discussed by Vasen [20], since it is known that LS
is caused by an mismatch repair gene defect and that
the hallmark of the syndrome is microsatellite instability
(MSI), more attention should be given to the so-calledCorrespondence: bmrossi@me.com
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Bethesda guidelines, which describe almost all clinical
conditions in which there is suspicion of LS and in
which a search for MSI is indicated, mainly early onset
of colorectal adenomas and cancer.
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